ARDX - Ardelyx Inc logo

Ardelyx Inc

ARDX

Ardelyx, Inc. develops and commercializes biopharmaceutical products for unmet medical needs. Its key offerings include IBSRELA for irritable bowel syndrome with constipation and XPHOZAH, which reduces serum phosphorus in chronic kidney disease patients.

βš•οΈ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago β†’$271today

Score Overview

1 Year
Score
Net Growth9.57%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth10.70%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score7.5
Net Growth64.78%
Net Trend80%
Net Income Consistencyβ€”
Rev Growth44x
Rev TrendEvery year
Revenue Consistencyβ€”
10 Years
Score
Net Growth50.44%
Net Trend60%
Net Income Consistency
Rev Growth18x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth-15x
Net Trend50%
Net Income Consistency
Rev Growth14x
Rev Trend75%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Ardelyx Inc has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ARDX

2020: 99.3% Β· 2021: 91.3% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 3.39β€”
1 Year2025-09-29
$ 5.63-39.79%
5 Years2021-09-29
$ 1.28164.84%
10 Years2016-09-29
$ 12.53-72.94%
All Time2014-06-19
$ 14.11-75.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 450M-$ 55M$ 281M
2025$ 407M-$ 61M$ 264M
2024$ 333M-$ 39M$ 250M
2023$ 124M-$ 66M$ 184M
2022$ 52M-$ 67M$ 123M
2021$ 10M-$ 158M$ 116M
2020$ 7M-$ 94M$ 186M
2019$ 5M-$ 94M$ 247M
2018$ 2M-$ 91M$ 168M
2017$ 42M-$ 64M$ 133M
2016$ 24M-$ 112M$ 200M
2015$ 24M-$ 29M$ 107M
IPO2014$ 31M-$ 3M$ 107M
ARDX - Ardelyx Inc logo

Ardelyx Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 7M to $ 407M and net income went from -$ 94M to -$ 61M. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 24M to $ 407M and net income went from -$ 29M to -$ 61M. Revenue increased in 9 of those 10 years; net income in 6.

Ardelyx Inc currently holds a 5-year HDB Score of 7.5 out of 10. How the HDB Score is calculated.

Membership

Continue ARDX’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies